Literature DB >> 11500727

Serum cytokines levels in Graves' disease.

M A Al-Humaidi1.   

Abstract

OBJECTIVE: The aim of the study was to look at the serum cytokines profile in newly diagnosed thyrotoxic patients with Graves' disease and to compare their cytokine levels with those of normal control subjects. Furthermore, the levels of T4, being an indicator of the severity of thyrotoxicosis, were also correlated with the Th1/Th2 and proinflammatory cytokines in Graves' disease patients.
METHODS: Serum IFN-gamma (Th1), IL-10 (Th2), inflammatory cytokines including IL-6, TNF-alpha, sCD23 and sIL-2R cytokine levels were measured in 28 patients with Graves' thyrotoxicosis and in 30 normal controls.
RESULTS: In Graves' disease patients, the levels of IFN-gamma (mean 142.1 +/- 29.53 units/ml), IL-10 (mean 583.8 +/- 253.3 pg/ml) and IL-4 (mean 132.4 +/- 44.52 pg/ml) were significantly higher than their corresponding levels in controls: IFN-gamma (mean 31.6 +/- 2.08 units/ml, P<0.001), IL-10 (mean 69.8 +/- 31.72 pg/ml, P<0.001) and IL-4 (mean 46.44 +/- 11.53 pg/ml). There was a marked increase in proinflammatory cytokines in Graves' disease patients: levels of IL-6 (481.5 +/- 192.3 pg/ml) and TNF-alpha (30.69 +/- 16.7 pg/ml) were significantly higher than those of normal controls for IL-6 (63.81 +/- 21.72 pg/ml, P<0.001) and TNF-alpha (8.81 +/- 1.72 pg/ml, P<0.001). Similarly the levels of sCD23 (mean 164 +/- 67.03 ng/ml) and sIL-2R (mean 2131 +/- 461.1 units/ml) were significantly higher in GD patients than in the control group (mean 31.24 +/- 11.53 ng/ml, P<0.001) and (mean 345.53 +/- 121.75 units/ml, P< 0.001) for sCD23 and sIL-2R. Furthermore, in thyrotoxic Graves' disease patients, we detected a positive correlation between free T4 and sIL-2R levels (r2 = 0.81, P<0.00), but no significant correlation was found between T4 and the other measured cytokines.
CONCLUSION: The elevated serum cytokines of Graves' thyrotoxic patients reflect the activation and interplay of mixed Th1 and Th2 cells which may be consistent with long standing inflammatory and destructive processes of thyroid gland. The clinical severity of hyperthyroidism in Graves' patients only correlated with sIL-2R.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11500727

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


  5 in total

1.  An association of interleukin-10 gene polymorphisms with Graves' disease in two Chinese populations.

Authors:  Nan Liu; Hao Lu; Feng Tao; Ting Guo; Changqin Liu; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2011-03-18       Impact factor: 3.633

2.  Dendritic cells infected with adenovirus expressing the thyrotrophin receptor induce Graves' hyperthyroidism in BALB/c mice.

Authors:  M Kita-Furuyama; Y Nagayama; P Pichurin; S M McLachlan; B Rapoport; K Eguchi
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

3.  The effects of royal jelly on autoimmunity in Graves' disease.

Authors:  Cihangir Erem; Orhan Deger; Ercüment Ovali; Yasam Barlak
Journal:  Endocrine       Date:  2006-10       Impact factor: 3.925

4.  Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.

Authors:  Sajad Moshkelgosha; Hedda Luise Verhasselt; Giulia Masetti; Anja Eckstein; Marian Ludgate; Utta Berchner-Pfannschmidt; Danila Covelli; Filippo Biscarini; Mareike Horstmann; Anke Daser; Astrid M Westendorf; Christoph Jesenek; Svenja Philipp; Salvador Diaz-Cano; J Paul Banga; Daryn Michael; Sue Plummer; Julian R Marchesi
Journal:  Microbiome       Date:  2021-02-16       Impact factor: 14.650

5.  Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells.

Authors:  Yanqun Li; Zi Wang; Ting Yu; Bingni Chen; Jinshun Zhang; Kunzhao Huang; Zhong Huang
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.